In the Claims:

Please amend the claims as follows:

Please replace the presently pending claims with the following claims:

Sub B1

1. (Amended) A method to inhibit p38α activity, which method comprises contacting said p38α with a compound of the formula:



(1)

A3

or the pharmaceutically acceptable salts thereof

wherein R^3 comprises a substituted or unsubstituted aromatic moiety, wherein said aromatic moiety is a monocyclic or fused bicyclic moiety containing 5-12 ring member atoms, optionally comprising one or more heteroatoms selected from O, S and N;

each Z is CR^2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N;

each R^2 is either

(i) independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, acyl, wherein each of alkyl, alkenyl, alkynyl and acyl may optionally contain 1-2 O, S or N, aryl, and arylalkyl, each of said aryl and arylalkyl optionally containing 1 or more O, S or N and wherein in each of the foregoing other than H may be unsubstituted or substituted with 1-3 substituents selected independently from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, aroyl, N-aryl, NH-alkylaryl, NH-aroyl, halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$, -NRCOOR, -NRSOR, $-NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C), and wherein any aryl or aroyl groups on said substituents may be further substituted by alkyl, alkenyl, alkynyl, halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$, -NRCOOR, -NRSOR, $-NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C), or

(ii) independently selected from the group consisting of halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$, -NRCOOR, NRSOR, $NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, NRSOR, $NRSO_2R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C);

A3 wherein L is a divalent moiety that provides a distance of 2-8Å between ring B and Ar′;

n is 0 or 1; and

B' cont Ar′ is a cyclic aliphatic, cyclic heteroaliphatic or a monocyclic or polycyclic aromatic moiety any of the foregoing optionally substituted with 1-3 substituents, wherein two of said substituents may form a 5-7 member cyclic optionally heterocyclic aliphatic ring and wherein Ar′ and any said substituents thereon forming a cyclic aliphatic ring, may optionally contain one or more ring atoms selected from O, S and N.

Please cancel claims 2-7.

8. (Amended) The method of claim 1 wherein any substituents on the aromatic or heteroaromatic moiety of R^3 are independently selected from the group consisting of halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$, -NRCOOR, -NRSOR, $-NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C) and alkyl (1-6C). A4

9. The method of claim 1 wherein said substituents on substituted Ar' are independently selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, aryl, alkylaryl, aroyl, N-aryl, NH-alkylaryl, NH-aroyl, halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$, -NRCOOR, -NRSOR, $-NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C),

and wherein any aryl or aroyl groups on said substituents may be further substituted by alkyl, alkenyl, alkynyl, halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$, -NRCOOR, -NRSOR, $-NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C).

A4

10. (Amended) The method of claim 9 wherein Ar' is phenyl, 2-, 3-, or 4-pyridyl, 2- or 4-pyrimidyl, indolyl, isoquinolyl, quinolyl, benzimidazolyl, benzotriazolyl, benzothiazolyl, benzofuranyl, pyridyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, or imidazolyl, all of which may optionally be substituted.

Please cancel claims 11 and 12.

A5

13. (Amended) The method of claim 1 wherein said optional substituents on R^2 are independently selected from the group consisting of R^4, halo, OR^4, $NR^4{}_2$, SR^4, $-OOCR^4$, $-NROCR^4$, $-COOR^4$, R^4CO, $-CONR^4{}_2$, $-SO_2NR^4{}_2$, CN, CF_3, and NO_2, wherein each R^4 is independently H, or optionally substituted alkyl (1-6C), or optionally substituted arylalkyl (7-12C) and wherein two R^4 or two substituents on said alkyl or arylalkyl taken together may form a fused aliphatic ring of 5-7 members.

Please cancel claim 14.

A6

15. (Amended) The method of claim 1 wherein L is $S(CR^2{}_2)_m$, $-NR^1SO_2(CR^2{}_2)_l$, $SO_2(CR^2{}_2)_m$, $SO_2NR^1(CR^2{}_2)_l$, $NR^1(CR^2{}_2)_m$, $NR^1CO(CR^2{}_2)_l$, $O(CR^2{}_2)_m$, or $OCO(CR^2{}_2)_l$, or



wherein Z is N or CH and wherein m is 0-4 and l is 0-3;

R^1 is H, alkyl or arylalkyl where the aryl moiety may be substituted by 1-3 substituents selected independently from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, aroyl, N-aryl, NH-alkylaryl, NH-aroyl, halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$, -NRCOOR, -NRSOR, $-NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C);

and wherein any aryl or aroyl groups on said substituents may be further substituted by alkyl, alkenyl, alkynyl, halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$,

-NRCOOR, -NRSOR, $-NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C); and

R^2 is as defined in claim 1.

16. (Amended) The method of claim 1 wherein the compound of formula (1) is selected from group consisting of

(a) the compounds listed in Table 2 below, wherein Z^5-Z^8 are CH; Z^3 is N; R^1 in compound No. 11 is 2-propyl; R^1 in compound No. 12 is 4-methoxyphenyl, and R^1 in compound No. 41 is 4-methoxybenzyl; and wherein L, Ar' and R^3 are as shown in Table 2:

A6

Table 2

Compound No.	L	Ar'	R^3
1	NH	4-pyridyl	2-chlorophenyl
2	NH	4-pyridyl	2,6-dichlorophenyl
3	NH	4-pyridyl	2-methylphenyl
4	NH	4-pyridyl	2-bromophenyl
5	NH	4-pyridyl	2-fluorophenyl
6	NH	4-pyridyl	2,6-difluorophenyl
7	NH	4-pyridyl	phenyl
8	NH	4-pyridyl	4-fluorophenyl
9	NH	4-pyridyl	4-methoxyphenyl
10	NH	4-pyridyl	3-fluorophenyl
11	NR^1	4-pyridyl	phenyl
12	NR^1	4-pyridyl	phenyl
13	$NHCH_2$	4-pyridyl	phenyl
14	$NHCH_2$	4-pyridyl	4-chlorophenyl
15	NH	3-pyridyl	phenyl
16	$NHCH_2$	2-pyridyl	phenyl
17	$NHCH_2$	3-pyridyl	phenyl
18	$NHCH_2$	2-pyridyl	phenyl
19	$NHCH_2CH_2$	2-pyridyl	phenyl
20	NH	6-pyrimidinyl	phenyl
21	NH	2-pyrimidinyl	phenyl
22	NH	Phenyl	phenyl
23	$NHCH_2$	Phenyl	3-chlorophenyl
24	NH	3-hydroxyphenyl	phenyl
25	NH	2-hydroxyphenyl	phenyl

Table 2			
Compound No.	L	Ar'	R^3
26	NH	4-hydroxyphenyl	phenyl
27	NH	4-indolyl	phenyl
28	NH	5-indolyl	phenyl
29	NH	4-methoxyphenyl	phenyl
30	NH	3-methoxyphenyl	phenyl
31	NH	2-methoxyphenyl	phenyl
32	NH	4-(2-hydroxyethyl)phenyl	phenyl
33	NH	3-cyanophenyl	phenyl
34	$NHCH_2$	2,5-difluorophenyl	phenyl
35	NH	4-(2-butyl)phenyl	phenyl
36	$NHCH_2$	4-dimethylaminophenyl	phenyl
38	NH	2-pyridyl	phenyl
39	$NHCH_2$	3-pyridyl	phenyl
40	NH	4-pyrimidyl	phenyl
41	NR^1	4-pyridyl	phenyl
42	NH	p-aminomethylphenyl	phenyl
43	$NHCH_2$	4-aminophenyl	phenyl
44	NH	4-pyridyl	3-chlorophenyl
45	NH	Phenyl	4-pyridyl
46	NH		phenyl
48	NH	2-benzylamino-3-pyridyl	phenyl
49	NH	2-benzylamino-4-pyridyl	phenyl
50	NH	3-benzyloxyphenyl	phenyl
51	NH	4-pyridyl	3-aminophenyl
52	NH	4-pyridyl	4-pyridyl
53	NH	4-pyridyl	2-naphthyl
54		4-pyridyl	phenyl
55		Phenyl	phenyl
56		2-pyridyl	phenyl
61	NH	4-pyridyl	2-trifluoromethyl phenyl
62	NH	4-aminophenyl	phenyl
64	NH	3-methoxyphenyl	2-fluorophenyl
65	NH	4-methoxyphenyl	2-fluorophenyl

A6

Table 2			
Compound No.	**L**	**Ar'**	**R^3**
66	NH	4-pyrimidinyl	2-fluorophenyl
67	NH	3-amino-4-pyridyl	phenyl
68	NH	4-pyridyl	2-benzylaminophenyl
69	NH	2-benzylaminophenyl	phenyl
70	NH	2-benzylaminophenyl	4-cyanophenyl
71	NH	3'-cyano-2-benzylaminophenyl	phenyl

A6

(b) the compounds listed in Table 3, below, wherein L is NH; Z^3 is N; Z^6 and Z^7 are CH and Z^5, Z^8, Ar' and R^3 are as shown in Table 3:

Table 3				
Compound No.	**Z^5**	**Z^8**	**Ar'**	**R^3**
72	CH	N	4-pyridyl	2-fluorophenyl
73	CH	N	4-pyridyl	2-chlorophenyl
74	CH	N	4-pyridyl	phenyl
75	N	N	4-pyridyl	phenyl
76	N	CH	4-pyridyl	phenyl

and

(c) the quinazoline derivatives listed in Table 4 below, wherein L is NH; Ar' is 4-pyridyl; Z^3, Z^5, and Z^8 are N; Z^6 or Z^7 are CR^2 as shown and each is otherwise N and wherein R^3 and R^2 are as shown in Table 4:

Table 4		
Compound No.	**R^3**	**R^2**
77	2-chlorophenyl	6,7-dimethoxy
78	2-fluorophenyl	6-nitro
79	2-fluorophenyl	6-amino
80	2-fluorophenyl	7-amino
81	2-fluorophenyl	6-(3-methoxybenzylamino)
82	2-fluorophenyl	6-(4-methoxybenzylamino)
83	2-fluorophenyl	6-(2-isobutylamino)
84	2-fluorophenyl	6-(4-methylmercaptobenzylamino)
85	2-fluorophenyl	6-(4-methoxybenzoyl amino)
86	4-fluorophenyl	7-amino
87	4-fluorophenyl	7-(3-methoxybenzylamino)

A6

17. (Amended) The method of claim 1 wherein the compound of formula (1) is selected from the group consisting of the following compounds:

Rul B2

B2
cont



A6





B2
Cont



A6







B^2 cont



A6







B2
cont



A6







B2 cont





A6





Serial No. Not yet assigned
Docket No. 219002028402

sd-53632

B2 cont



A6







Serial No. Not yet assigned
Docket No. 219002028402

sd-53632

B2 Cont

A6









B2 cont



A6





B2 cont



A6







B2 cont

A6







B2 cont



Ab







B2 cont

A6









B2 cont



A6







B2 cont





A6







B2 cont

A6







B2 cont



A6





B2 cont





A6





B2
cont



A6







Serial No. Not yet assigned
Docket No. 219002028402

sd-53632

B2 cont



A6







B^2 cont

A6







Serial No. Not yet assigned
Docket No. 219002028402

B2 cont





A6





B2 cont



A6







18. (Amended) A pharmaceutical composition for treating conditions characterized by enhanced p38α kinase activity which composition comprises

an amount of a compound of the formula



(1)

A6

or the pharmaceutically acceptable salts thereof

wherein R^3;

each Z;

each R^2;

L;

n; and

Ar' are as defined in claim 1 which is effective to inhibit p38α kinase activity in admixture with at least one pharmaceutically acceptable excipient appropriate for administering to a subject exhibiting enhanced p38α kinase activity.

19. The composition of claim 18 which further contains an additional therapeutic agent.

20. The composition of claim 19 wherein said additional therapeutic agent is a corticosteroid, a monoclonal antibody, or an inhibitor of cell division.

Please cancel claims 21-22.

Please add the following claims:

A7

23. (New) The method of claim 1 wherein

L is $-R^1N(CH_2)_n-$ wherein R^1 is H or is alkyl (1-6C) or arylalkyl optionally substituted on the aryl group with 1-3 substituents independently selected from alkyl (1-6C), halo, OR, NR_2,

SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, $-SO_2NR_2$, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C) and n is 0, 1 or 2; and

(a) Ar′ is phenyl, substituted with at least one group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C), or pyridyl, indolyl, or pyrimidyl, each optionally substituted with at least one group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); and

A7 R^3 is phenyl optionally substituted with 1-3 substituents which substituents are selected from the group consisting of alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, $-SO_2NR_2$, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); or

(b) Ar′ is phenyl, pyridyl, indolyl, or pyrimidyl, each optionally substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); and

R^3 is phenyl substituted with 1-3 substituents which substituents are selected from the group consisting of alkyl (1-6C), halo, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, $-SO_2NR_2$, CN, and CF_3, wherein each R is independently H or lower alkyl (1-4C); or

(c) Ar′ is phenyl substituted with a group selected from the group consisting of optionally substituted NR_2, SR, -NROCR, RCO, $-CONR_2$, SO_2NR_2, CN, and CF_3, wherein each R is independently H or lower alkyl (1-4C); or pyridyl substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); or indolyl or pyrimidyl, each optionally substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); and

R^3 is phenyl optionally substituted with 1-3 substituents which substituents are selected from the group consisting of alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR,

-$CONR_2$, -SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); or

(d) Ar' is phenyl, pyridyl, indolyl, or pyrimidyl, each optionally substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, -$CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); and

R^3 is phenyl substituted with 1-3 substituents which substituents are selected from the group consisting of alkyl (1-6C), halo, OR, SR, -OOCR, -NROCR, RCO, -COOR, -$CONR_2$, -SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C).

A7

24. (New) The method of claim 1 wherein the compound of formula 1 is selected from the group consisting of

2-phenyl-4-(4-pyridylamino)-quinazoline;

2-(2-bromophenyl)-4-(4-pyridylamino)-quinazoline;

2-(2-chlorophenyl)-4-(4-pyridylamino)-quinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino)-quinazoline;

2-(2-methylphenyl)-4-(4-pyridylamino)-quinazoline;

2-(4-fluorophenyl)-4-(4-pyridylamino)-quinazoline;

2-(3-methoxyanilyl)-4-(4-pyridylamino)-quinazoline;

2-(2,6-dichlorophenyl)-4-(4-pyridylamino)-quinazoline;

2-(2,6-dibromophenyl)-4-(4-pyridylamino)-quinazoline;

2-(2,6-difluorophenyl)-4-(4-pyridylamino)-quinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino)-6, 7-dimethoxyquinazoline;

2-(4-fluorophenyl)-4-(4-pyridylamino)-6, 7-dimethoxyquinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino)-6-nitroquinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino -6-aminoquinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino)-7-aminoquinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino)-6-(3-methoxybenzylamino)-quinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino)-6-(4-methoxybenzylamino)-quinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino)-6-(2-isobutylamino)-quinazoline; and

2-(2-fluorophenyl)-4-(4-pyridylamino)-6-(4-methylmercaptobenzylamino)-quinazoline.

25. (New) The composition of claim 18 wherein any substituents on the aromatic or heteroaromatic moiety of R^3 are independently selected from the group consisting of alkyl (1-6C), halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$, -NRCOOR, -NRSOR, $-NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C).

A7

26. (New) The composition of claim 18 wherein said substituents on substituted Ar' are independently selected from the group consisting of optionally substituted alkyl, alkenyl, alkynyl, aryl, alkylaryl, aroyl, N-aryl, NH-alkylaryl, NH-aroyl, halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$, -NRCOOR, -NRSOR, $-NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C),

and wherein any aryl or aroyl groups on said substituents may be further substituted by alkyl, alkenyl, alkynyl, halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$, -NRCOOR, -NRSOR, $-NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C).

27. (New) The composition of claim 26 wherein Ar' is phenyl, 2-, 3-, or 4-pyridyl, 2- or 4-pyrimidyl, indolyl, isoquinolyl, quinolyl, benzimidazolyl, benzotriazolyl, benzothiazolyl, benzofuranyl, pyridyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, or imidazolyl, all of which may optionally be substituted.

28. (New) The composition of claim 18 wherein said optional substituents on R^2 are independently selected from the group consisting of R^4, halo, OR^4, NR^4_2, SR^4, $-OOCR^4$, $-NROCR^4$, $-COOR^4$, R^4CO, $-CONR^4_2$, $-SO_2NR^4_2$, CN, CF_3, and NO_2, wherein each R^4 is independently H, or optionally substituted alkyl (1-6C), or optionally substituted arylalkyl (7-12C) and wherein two R^4 or two substituents on said alkyl or arylalkyl taken together may form a fused aliphatic ring of 5-7 members.

29. (New) The composition of claim 18 wherein L is $S(CR^2{}_2)_m$, $-NR^1SO_2(CR^2{}_2)_l$, $SO_2(CR^2{}_2)_m$, $SO_2NR^1(CR^2{}_2)_l$, $NR^1(CR^2{}_2)_m$, $NR^1CO(CR^2{}_2)_l$, $O(CR^2{}_2)_m$, or $OCO(CR^2{}_2)_l$, or



A7

wherein Z is N or CH and wherein m is 0-4 and l is 0-3;

R^1 is H, alkyl or arylalkyl where the aryl moiety may be substituted by 1-3 substituents selected independently from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, aroyl, N-aryl, NH-alkylaryl, NH-aroyl, halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$, -NRCOOR, -NRSOR, $-NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C);

and wherein any aryl or aroyl groups on said substituents may be further substituted by alkyl, alkenyl, alkynyl, halo, OR, NR_2, SR, -SOR, $-SO_2R$, -OCOR, -NRCOR, $-NRCONR_2$, -NRCOOR, -NRSOR, $-NRSO_2R$, $-OCONR_2$, RCO, -COOR, $-SO_3R$, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or alkyl (1-4C); and

R^2 is as defined in claim 18.

30. (New) The composition of claim 18 wherein the compound of formula (1) is selected from the group consisting of

(a) the compounds listed in Table 2 below, wherein Z^5-Z^8 are CH; Z^3 is N; R^1 in compound No. 11 is 2-propyl; R^1 in compound No. 12 is 4-methoxyphenyl, and R^1 in compound No. 41 is 4-methoxybenzyl; and wherein L, Ar' and R^3 are as shown in Table 2:

Table 2

Compound No.	L	Ar'	R^3
1	NH	4-pyridyl	2-chlorophenyl
2	NH	4-pyridyl	2,6-dichlorophenyl
3	NH	4-pyridyl	2-methylphenyl
4	NH	4-pyridyl	2-bromophenyl
5	NH	4-pyridyl	2-fluorophenyl
6	NH	4-pyridyl	2,6-difluorophenyl

A1

Table 2			
Compound No.	L	Ar'	R^3
7	NH	4-pyridyl	phenyl
8	NH	4-pyridyl	4-fluorophenyl
9	NH	4-pyridyl	4-methoxyphenyl
10	NH	4-pyridyl	3-fluorophenyl
11	NR^1	4-pyridyl	phenyl
12	NR^1	4-pyridyl	phenyl
13	$NHCH_2$	4-pyridyl	phenyl
14	$NHCH_2$	4-pyridyl	4-chlorophenyl
15	NH	3-pyridyl	phenyl
16	$NHCH_2$	2-pyridyl	phenyl
17	$NHCH_2$	3-pyridyl	phenyl
18	$NHCH_2$	2-pyridyl	phenyl
19	$NHCH_2CH_2$	2-pyridyl	phenyl
20	NH	6-pyrimidinyl	phenyl
21	NH	2-pyrimidinyl	phenyl
22	NH	Phenyl	phenyl
23	$NHCH_2$	Phenyl	3-chlorophenyl
24	NH	3-hydroxyphenyl	phenyl
25	NH	2-hydroxyphenyl	phenyl
26	NH	4-hydroxyphenyl	phenyl
27	NH	4-indolyl	phenyl
28	NH	5-indolyl	phenyl
29	NH	4-methoxyphenyl	phenyl
30	NH	3-methoxyphenyl	phenyl
31	NH	2-methoxyphenyl	phenyl
32	NH	4-(2-hydroxyethyl)phenyl	phenyl
33	NH	3-cyanophenyl	phenyl
34	$NHCH_2$	2,5-difluorophenyl	phenyl
35	NH	4-(2-butyl)phenyl	phenyl
36	$NHCH_2$	4-dimethylaminophenyl	phenyl
38	NH	2-pyridyl	phenyl
39	$NHCH_2$	3-pyridyl	phenyl
40	NH	4-pyrimidyl	phenyl
41	NR^1	4-pyridyl	phenyl
42	NH	p-aminomethylphenyl	phenyl
43	$NHCH_2$	4-aminophenyl	phenyl

Table 2			
Compound No.	**L**	**Ar'**	**R^3**
44	NH	4-pyridyl	3-chlorophenyl
45	NH	Phenyl	4-pyridyl
46	NH		phenyl
48	NH	2-benzylamino-3-pyridyl	phenyl
49	NH	2-benzylamino-4-pyridyl	phenyl
50	NH	3-benzyloxyphenyl	phenyl
51	NH	4-pyridyl	3-aminophenyl
52	NH	4-pyridyl	4-pyridyl
53	NH	4-pyridyl	2-naphthyl
54		4-pyridyl	phenyl
55		Phenyl	phenyl
56		2-pyridyl	phenyl
61	NH	4-pyridyl	2-trifluoromethyl phenyl
62	NH	4-aminophenyl	phenyl
64	NH	3-methoxyphenyl	2-fluorophenyl
65	NH	4-methoxyphenyl	2-fluorophenyl
66	NH	4-pyrimidinyl	2-fluorophenyl
67	NH	3-amino-4-pyridyl	phenyl
68	NH	4-pyridyl	2-benzylaminophenyl
69	NH	2-benzylaminophenyl	phenyl
70	NH	2-benzylaminophenyl	4-cyanophenyl
71	NH	3'-cyano-2-benzylaminophenyl	phenyl

A7

(b) the compounds listed in Table 3, below, wherein L is NH; Z^3 is N; Z^6 and Z^7 are CH and Z^5, Z^8, Ar' and R^3 are as shown in Table 3:

Table 3				
Compound No.	**Z^5**	**Z^8**	**Ar'**	**R^3**
72	CH	N	4-pyridyl	2-fluorophenyl
73	CH	N	4-pyridyl	2-chlorophenyl
74	CH	N	4-pyridyl	phenyl
75	N	N	4-pyridyl	phenyl
76	N	CH	4-pyridyl	phenyl

A7

and

(c) the quinazoline derivatives listed in Table 4 below, wherein L is NH; Ar' is 4-pyridyl; Z^3, Z^5, and Z^8 are N; Z^6 or Z^7 are CR^2 as shown and each is otherwise N and wherein R^3 and R^2 are as shown in Table 4:

Table 4		
Compound No.	**R^3**	**R^2**
77	2-chlorophenyl	6,7-dimethoxy
78	2-fluorophenyl	6-nitro
79	2-fluorophenyl	6-amino
80	2-fluorophenyl	7-amino
81	2-fluorophenyl	6-(3-methoxybenzylamino)
82	2-fluorophenyl	6-(4-methoxybenzylamino)
83	2-fluorophenyl	6-(2-isobutylamino)
84	2-fluorophenyl	6-(4-methylmercaptobenzylamino)
85	2-fluorophenyl	6-(4-methoxybenzoyl amino)
86	4-fluorophenyl	7-amino
87	4-fluorophenyl	7-(3-methoxybenzylamino)

31. (New) The composition of claim 18 wherein the compound of formula (1) is selected from the group consisting of the following compounds:



A7







A7









A7









A7











A7







A7









A7









A7







A7









A7







A7









A7







Serial No. Not yet assigned
Docket No. 219002028402

sd-53632



A7











A7









A7







A7









A7







A7











A7







A7







A7









A7







32. (New) The composition of claim 18 wherein

L is $-R^1N(CH_2)_n-$;

L is $-R^1N(CH_2)_n-$ wherein R^1 is H or is alkyl (1-6C) or arylalkyl optionally substituted on the aryl group with 1-3 substituents independently selected from alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, $-SO_2NR_2$, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C) and n is 0, 1 or 2; and

A7

(a) Ar′ is phenyl, substituted with at least one group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C), or pyridyl, indolyl, or pyrimidyl, each optionally substituted with at least one group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); and

R^3 is phenyl optionally substituted with 1-3 substituents which substituents are selected from the group consisting of alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, $-SO_2NR_2$, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); or

(b) Ar′ is phenyl, pyridyl, indolyl, or pyrimidyl, each optionally substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); and

R^3 is phenyl substituted with 1-3 substituents which substituents are selected from the group consisting of alkyl (1-6C), halo, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, $-SO_2NR_2$, CN, and CF_3, wherein each R is independently H or lower alkyl (1-4C); or

(c) Ar′ is phenyl substituted with a group selected from the group consisting of optionally substituted NR_2, SR, -NROCR, RCO, $-CONR_2$, SO_2NR_2, CN, and CF_3, wherein each R is independently H or lower alkyl (1-4C); or pyridyl substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, $-CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); or indolyl or pyrimidyl, each optionally substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR_2, SR, -OOCR,

-NROCR, RCO, -COOR, -$CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); and

R^3 is phenyl optionally substituted with 1-3 substituents which substituents are selected from the group consisting of alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, -$CONR_2$, -SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); or

A7

(d) Ar′ is phenyl, pyridyl, indolyl, or pyrimidyl, each optionally substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR_2, SR, -OOCR, -NROCR, RCO, -COOR, -$CONR_2$, SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C); and

R^3 is phenyl substituted with 1-3 substituents which substituents are selected from the group consisting of alkyl (1-6C), halo, OR, SR, -OOCR, -NROCR, RCO, -COOR, -$CONR_2$, -SO_2NR_2, CN, CF_3, and NO_2, wherein each R is independently H or lower alkyl (1-4C).

33. (New) The composition of claim 18 wherein the compound of formula 1 is selected from the group consisting of

2-phenyl-4-(4-pyridylamino)-quinazoline;

2-(2-bromophenyl)-4-(4-pyridylamino)-quinazoline;

2-(2-chlorophenyl)-4-(4-pyridylamino)-quinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino)-quinazoline;

2-(2-methylphenyl)-4-(4-pyridylamino)-quinazoline;

2-(4-fluorophenyl)-4-(4-pyridylamino)-quinazoline;

2-(3-methoxyanilyl)-4-(4-pyridylamino)-quinazoline;

2-(2,6-dichlorophenyl)-4-(4-pyridylamino)-quinazoline;

2-(2,6-dibromophenyl)-4-(4-pyridylamino)-quinazoline;

2-(2,6-difluorophenyl)-4-(4-pyridylamino)-quinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino)-6, 7-dimethoxyquinazoline;

2-(4-fluorophenyl)-4-(4-pyridylamino)-6, 7-dimethoxyquinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino)-6-nitroquinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino -6-aminoquinazoline;

2-(2-fluorophenyl)-4-(4-pyridylamino)-7-aminoquinazoline;

A7

2-(2-fluorophenyl)-4-(4-pyridylamino)-6-(3-methoxybenzylamino)-quinazoline;
2-(2-fluorophenyl)-4-(4-pyridylamino)-6-(4-methoxybenzylamino)-quinazoline;
2-(2-fluorophenyl)-4-(4-pyridylamino)-6-(2-isobutylamino)-quinazoline; and
2-(2-fluorophenyl)-4-(4-pyridylamino)-6-(4-methylmercaptobenzylamino)-quinazoline.